Barclays PLC Has $442,000 Stock Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Barclays PLC increased its holdings in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by 158.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,345 shares of the biotechnology company’s stock after purchasing an additional 16,772 shares during the quarter. Barclays PLC owned 0.16% of Rigel Pharmaceuticals worth $442,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Empire Financial Management Company LLC acquired a new position in Rigel Pharmaceuticals in the 3rd quarter worth $231,000. PDT Partners LLC bought a new stake in shares of Rigel Pharmaceuticals in the third quarter valued at about $322,000. BNP Paribas Financial Markets boosted its position in shares of Rigel Pharmaceuticals by 1,199.2% during the third quarter. BNP Paribas Financial Markets now owns 21,008 shares of the biotechnology company’s stock worth $340,000 after buying an additional 19,391 shares during the period. FMR LLC grew its holdings in shares of Rigel Pharmaceuticals by 119.4% during the third quarter. FMR LLC now owns 48,105 shares of the biotechnology company’s stock worth $778,000 after buying an additional 26,184 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its position in Rigel Pharmaceuticals by 34.5% in the 3rd quarter. Los Angeles Capital Management LLC now owns 74,502 shares of the biotechnology company’s stock valued at $1,205,000 after buying an additional 19,094 shares during the last quarter. 66.23% of the stock is currently owned by institutional investors and hedge funds.

Rigel Pharmaceuticals Stock Performance

NASDAQ RIGL opened at $20.13 on Friday. Rigel Pharmaceuticals, Inc. has a 52-week low of $7.48 and a 52-week high of $29.82. The stock has a market cap of $354.49 million, a PE ratio of 143.80 and a beta of 1.31. The firm has a 50-day moving average of $21.04 and a 200-day moving average of $15.75.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. B. Riley increased their price objective on shares of Rigel Pharmaceuticals from $17.00 to $27.00 and gave the stock a “neutral” rating in a research note on Friday, December 6th. HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Rigel Pharmaceuticals in a research report on Tuesday, January 14th. Cantor Fitzgerald boosted their price target on Rigel Pharmaceuticals from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 10th. Citigroup raised their target price on shares of Rigel Pharmaceuticals from $40.00 to $49.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. Finally, StockNews.com raised shares of Rigel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 18th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Rigel Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $36.20.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.